10 results about "Activated Lymphocyte" patented technology

The present invention belongs to the technical field of cancer immunotherapy, and particularly relates to a cholesterol-modified cationic liposome tumor vaccine, a preparation method therefor, and use thereof. In order to solve the problems of poor targeting and strong side effects of TLR agonists in anti-tumor treatment, the present invention provides a cationic liposome prepared from a cholesterol-modified 1V209 molecule, a cationic lipid component, cholesterol, and DSPE-PEG2000, and then the cationic liposome and ovalbumin 5 form the tumor vaccine by electrostatic adsorption. Animal experiments show that the vaccine can induce antigen-specific CD8+ T cells, activate lymphocytes, and generate stronger antigen cross-presentation, more memory T cells, antibodies, and cytokines. Prophylactic inoculation with the vaccine can significantly delay the progression of mouse melanoma and lymphoma and prolong the survival of mice. The combination use of the vaccine and a PD-1 checkpoint inhibitor can further enhance the anti-tumor effect. Therefore, the vaccine is a promising cancer vaccine.

The present application provides chimeric anti-CD27 antibody molecules and encoding nucleic acids and expression vectors thereof. The anti-CD27 antibody molecules of the present application can specifically bind to CD27 and have effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

The present application provides a chimeric anti-CD27 antibody molecule composition and its application. The anti-CD27 antibody molecule of the present application can specifically bind to CD27 and has the effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

The invention provides an in-vitro or ex-vivo method of expanding lymphocytes and a population of expanded tumor infiltrating lymphocytes (TILs) for use in a method for treating cancer comprising providing a population of lymphocytes, wherein the lymphocytes are from a biological sample; culturing the lymphocytes in a growth medium; expanding the lymphocytes in an expansion medium comprising nutrients and differentiation factors and / or cytokines, wherein the differentiations factors and / or cytokines comprise or consist of interleukin-2, interleukin-7, interleukin-15, and interleukin-21; obtaining expanded lymphocytes.

The present application provides recombinant anti-CD27 antibody molecules, and encoding nucleic acids and expression vectors thereof. The anti-CD27 antibody molecules of the present application can specifically bind to CD27, and have effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

The present invention provides a hyperthermia-induced gut microbiome- mediated modulation of the host immune system for the treatment of gastric / gastric MALT / Duodenum cancer; the said system uses a wild type / non-pathogenic / attenuated strain coated with iron oxide nanoparticles to specifically target the cancerous tissue by applying an external field around the gastric tissue the said iron oxide generates heat on bacteria surface and causes lysis of bacteria in the tumor microenvironment; the lysis of bacteria triggers various potent immune activator and cytokines to activate antigen-presenting cells including lymphocytes and macrophages; the said antigen presenting cell further, eliminates cancer cell from the gut microenvironment and eventually clean tumor microenvironment. Additionally, the activated lymphocytes will be antigenic memory against bacterial particles and cancer tissues. Furthermore, the said treatment system does not involve the use of any chemotherapeutic drug or radiation treatment and, thus, precludes undesirable side effects of chemotherapy as well as minimizes toxicity.

The present application provides anti-CD27 antibody compositions and uses thereof. The anti-CD27 antibodies of the present application are capable of specifically binding to CD27 and have effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

The present application relates to the field of cell therapy, in particular to a regulatory T cell targeting IL12RB1 and use thereof. The regulatory T cell provided by the present application comprises a P40 subunit or a mutant thereof. The present application uses a natural protein sequence, which can avoid the immunogenicity risk of antigens caused by scFv; and enables Treg cells to home to inflammatory sites and inhibit activated lymphocytes.

The application relates to a preparation method and application of M1 type macrophages, and the method comprises the following steps: adding activated mouse lymphocytes to a culture system of mouse macrophages for co-culture to obtain M1 type macrophages. The application explores the identification of CD3 / CD28 activated lymphocytes, the influence of activated lymphocytes on the macrophage morphology and the influence of activated lymphocytes on the macrophage subtype, and provides a brand-new method for obtaining mouse M1 type macrophages. The application solves the problem that the stimulation of macrophages by using a recombinant IFN-gamma alone is not enough to completely induce the macrophage polarization. The application provides a new in-vitro mouse M1 type macrophage model for experimental research. The M1 type macrophages induced by the activated lymphocytes can better simulate the immune response process in the body, the required cell state is obtained by using the in-vivo co-culture of two kinds of cells, and compared with the dependence on the exogenous addition of viruses or compounds, the application can effectively avoid many potential risks and disadvantages.

The present invention relates to a method for mass proliferation and culturing of Vδ1 T cells, Vδ1 T cells produced by the method, and a use thereof, the method comprising a step for activating lymphocytes from a biological sample containing the lymphocytes, a step for isolating Vδ1 T cells from the activated cell population, and a step for proliferating and culturing the isolated Vδ1 T cells by treating the isolated Vδ1 T cells with an anti-TCRVδ1 antibody. The method for mass proliferation and culturing according to the present invention makes it possible to produce Vδ1 T cells without artificial antigen-presenting cells, while maintaining an excellent proliferation rate and purity, and thus can be effectively used in related technical fields such as cancer treatment using Vδ1 T cells.